The Quantellect read.As of Nov 19, 2026, 11 active firms cover Sarepta Therapeutics Inc: 5 rate it Buy or better, 3 sit at Neutral, and 3 rate it Sell or worse, a neutral consensus. The target range is very wide, $5.00 to $38.00 (about 7.6x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $24.20 sits 66% above the current $14.54. The rating mix has stayed broadly stable, with Buy-side ratings easing from 7 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.43 next quarter toward $1.48 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 active firms
Neutral
Strong Buy00%
Buy545%
Neutral327%
Sell327%
Strong Sell00%
Based on 11 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$24.20
+66.4% upside
Average target across 10 active firms as of Nov 19, 2026 vs $14.54 current
Highest Target$38.00
Average Target$24.20
Lowest Target$5.00
Detailed analyst forecasts for SRPT
Showing 1–11 of 11 named analysts shown · 11 active firms in the rating projection
As of Nov 19, 2026, 5 of 11 active firms rate SRPT a Buy (3 Neutral, 3 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SRPT EPS & revenue forecast
EPS · NEXT QUARTER
$0.43
Range $-0.02 – $0.96 · 6 analysts · -86% YoY
Next period, 6 analysts expect Sarepta Therapeutics Inc to earn $0.43 a share (range $-0.02 – $0.96), versus $3.16 a year earlier. Full-year consensus is $3.95, growing to $1.48 the year after.
REVENUE · NEXT QUARTER
$356.3M
Range $320.7M – $383.9M · 6 analysts · -51% YoY
Revenue is expected to reach $356.3M (range $320.7M – $383.9M), -51.2% year-over-year. Full-year consensus is $1.9B, rising to $1.4B next year.
Top analysts covering Sarepta Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SRPT.
#1
Anupam Rama
JP Morgan · Rank #171
Neutral
$20.00+37.5% to target
Overall win rate
48%
+ Follow
#2
Kristen Kluska
Cantor Fitzgerald · Rank #232
Neutral
$21.00+44.4% to target
Overall win rate
38%
+ Follow
#3
Joseph Schwartz
Leerink Partners · Rank #242
Neutral
$15.00+3.2% to target
Overall win rate
36%
+ Follow
#4
Debjit Chattopadhyay
Guggenheim · Rank #248
Buy
$19.00+30.7% to target
Overall win rate
39%
+ Follow
#5
Mitchell Kapoor
HC Wainwright & Co. · Rank #305
Sell
$5.00-65.6% to target
Overall win rate
33%
+ Follow
SRPT stock forecast FAQ
What is SRPT's average 12-month price target?+
The 10 active firms with a live target average $24.20 for Sarepta Therapeutics Inc over the next 12 months, ranging from a $38.00 high to a $5.00 low, as of Nov 19, 2026.
Is SRPT stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 11 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 3 rate it Neutral, and 3 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SRPT?+
The Street-high target is $38.00 (Wells Fargo), and the Street-low is $5.00 (HC Wainwright & Co.). The average of all 10 active-firm targets is $24.20.
How many active Wall Street firms cover SRPT?+
11 active firms have a recognized rating on Sarepta Therapeutics Inc as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SRPT?+
Among analysts who currently cover SRPT, Anupam Rama of JP Morgan has the strongest overall Quantellect track record (Rank #171). Their current call is Neutral with a $20.00 target.
What is Sarepta Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $0.43 per share (range $-0.02 – $0.96) across 6 analysts. Full-year EPS is projected at $3.95, rising to $1.48 the following year.
How much revenue is Sarepta Therapeutics Inc expected to report next quarter?+
Consensus revenue is $356.3M (range $320.7M – $383.9M). Full-year revenue is projected at $1.9B, growing to $1.4B next year.
Have analysts been upgrading or downgrading SRPT lately?+
As of Nov 19, 2026, 5 of 11 active firms rate SRPT a Buy (3 Neutral, 3 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SRPT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.